IL7R and acute lymphoblastic leukemia: Additionally, other potentially druggable kinases reported for T-ALL include the JAK-family member tyrosine kinase 2 (TYK2) which can be activated either by rare gain-of-function mutations or IL-10 signaling8,9, the cell cycle regulators Polo-like kinases (PLKs) and Aurora kinases (AURKs)10,11, and the PIM1 kinase which can be upregulated by active IL-7 signaling, upon glucocorticoid-induced IL7RA expression, or in the presence of IL-7R pathway mutations12,13.